Early insulin therapy won’t lower CV events: study
However, importantly, the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) study is reassuring about the safety of insulin therapy and should be an impetus for more aggressive early treatment, said Australian investigator Associate Professor Michael D’Emden.
“Our fears about using insulin early have been dispelled by this study,” he told MO.
The ORIGIN study, funded by Lantus manufacturer Sanofi and led by academics in 40 countries, included 12,500 elderly people (150 Australians) with CV risk factors and type 2 diabetes, impaired fasting glucose or impaired glucose tolerance who were randomised to insulin glargine or standard care and followed for a median 6.2 years.
No difference between the groups was seen in a combined primary endpoint of nonfatal myocardial infarction, nonfatal stroke and death from CV causes, researchers reported at the American Diabetes Association 72nd annual scientific